Clinical significance of Gata‐1, Gata‐2, EKLF, and c‐MPL expression in acute myeloid leukemia | Zendy

Ayala Rosa M. | Zendy; MartínezLópez Joaquín | Zendy; Albízua Enriqueta | Zendy; Diez Amalia | Zendy; Gilsanz Florinda | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Clinical significance of Gata‐1, Gata‐2, EKLF, and c‐MPL expression in acute myeloid leukemia

Author(s) -

Ayala Rosa M.,

MartínezLópez Joaquín,

Albízua Enriqueta,

Diez Amalia,

Gilsanz Florinda

Publication year - 2009

Publication title -

american journal of hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.456

H-Index - 105

eISSN - 1096-8652

pISSN - 0361-8609

DOI - 10.1002/ajh.21332

Subject(s) - cd34 , myeloid leukemia , bone marrow , medicine , leukemia , cancer research , myeloid , overall survival , immunology , oncology , biology , stem cell , genetics

The aim of this study was to evaluate the biological correlation and prognostic impact of Gata‐1, Gata‐2, EKLF, and c‐MPL transcript level in a group of 41 acute mieloid leukemia (AML) patients. Gata‐1 overexpression was related to advanced age and a low percentage of bone marrow blasts and was associated with the expression of CD34 antigen and lymphoid T markers. The negative impact of Gata‐1 expression on the probability of achieving complete remission has been confirmed. Gata‐2 overexpression was associated with a low percentage of blasts in BM and males. Expression of c‐MPL was associated with CD34+ AML and M2 FAB AML subtype. A higher expression of EKLF was found in secondary AML versus primary AML. Nevertheless, patients expressing EKLF had a longer overall survival and event free survival than those patients that did not express EKLF. Our study has identified expression of EKLF as a factor with a favorable impact on prognosis in AML. Am. J. Hematol, 2009. © 2008 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research